Neuroimaging as a Tool for Advancing Pediatric Psychopharmacology
- 3 February 2025
- journal article
- review article
- Published by Springer Nature in Pediatric Drugs
- Vol. 27 (3) , 307-330
Abstract
Neuroimaging, specifically magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and positron emission tomography (PET), plays an important role in improving the therapeutic landscape of pediatric neuropsychopharmacology by detecting target engagement, pathway modulation, and disease-related changes in the brain. This review provides a comprehensive update on the application of neuroimaging to detect neural effects of psychotropic medication in pediatrics. Additionally, we discuss opportunities and challenges for expanding the use of neuroimaging to advance pediatric neuropsychopharmacology. PubMed and Embase were searched for studies published between 2012 and 2024 reporting neural effects of attention deficit hyperactivity disorder (ADHD) medications (e.g., methylphenidate, amphetamine, atomoxetine, guanfacine), selective serotonin reuptake inhibitors (e.g., fluoxetine, escitalopram, sertraline), serotonin/norepinephrine reuptake inhibitors (e.g., duloxetine, venlafaxine), second-generation antipsychotics (e.g., aripiprazole, olanzapine, risperidone, quetiapine, ziprasidone), and others (e.g., lithium, carbamazepine, lamotrigine, ketamine, naltrexone) used to treat pediatric psychiatric conditions. Of the studies identified (N = 57 in 3314 pediatric participants), most (86%, total participants n = 3045) used MRI to detect functional pathway modulation or anatomical changes. Fewer studies (14%, total participants n = 269) used MRS to understand neurochemical modulation. No studies used PET. Studies that included healthy controls detected normalization of disease-altered pathways following treatment. Studies that focused on affected youth detected neuromodulation following single-dose and ongoing treatment. Neuroimaging is positioned to serve as a biomarker capable of demonstrating acute brain modulation, predicting clinical response, and monitoring disease, yet biomarker validation requires further work. Neuroimaging is also well suited to fill the notable knowledge gap of long-term neuromodulatory effects of psychotropic medications in the context of ongoing brain development in children and adolescents. Future studies can leverage advancements in neuroimaging technology, acquisition, and analysis to fill these gaps and accelerate the discovery of novel therapeutics, leading to more effective prescribing and ensuring faster recovery.Keywords
Funding Information
- National Institute of Mental Health (K23MH130728)
- National Center for Advancing Translational Sciences (KL2TR002367)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P30HD106451)
This publication has 131 references indexed in Scilit:
- Parameter Space and Potential for Biomarker Development in 25 Years of fMRI Drug Cue ReactivityJAMA Psychiatry, 2024
- Minimum Reporting Standards for in vivo Magnetic Resonance Spectroscopy (MRSinMRS): Experts' consensus recommendationsNMR in Biomedicine, 2021
- PET technology for drug development in psychiatryNeuropsychopharmacology Reports, 2020
- Association of Intrinsic Brain Architecture With Changes in Attentional and Mood Symptoms During DevelopmentJAMA Psychiatry, 2020
- Inverse fluoxetine effects on inhibitory brain activation in non-comorbid boys with ADHD and with ASDPsychopharmacology, 2014
- COMT genotype affects brain white matter pathways in attention-deficit/hyperactivity disorderHuman Brain Mapping, 2014
- Pattern classification of response inhibition in ADHD: Toward the development of neurobiological markers for ADHDHuman Brain Mapping, 2013
- Common and Unique Therapeutic Mechanisms of Stimulant and Nonstimulant Treatments for Attention-Deficit/Hyperactivity DisorderArchives of General Psychiatry, 2012
- Deep phenotyping for precision medicineHuman Mutation, 2012
- The role of fMRI in drug discoveryJournal of Magnetic Resonance Imaging, 2006